{
    "id": 25252,
    "fullName": "STAG3 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "STAG3 dec exp indicates decreased expression of the Stag3 protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10734,
        "geneSymbol": "STAG3",
        "terms": [
            "STAG3"
        ]
    },
    "variant": "dec exp",
    "createDate": "08/17/2016",
    "updateDate": "01/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7795,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag3 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26043,
                "profileName": "BRAF mut STAG3 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7796,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag3 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) in culture and in cell line xenograft models (PMID: 27500726).",
            "molecularProfile": {
                "id": 26043,
                "profileName": "BRAF mut STAG3 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7797,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing both Stag2 and Stag3 expression levels through shRNA knockdown in BRAF mutated melanoma cells resulted in further decreased response to Zelboraf (vemurafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26044,
                "profileName": "BRAF mut STAG2 dec exp STAG3 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26041,
            "profileName": "STAG3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26043,
            "profileName": "BRAF mut STAG3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26044,
            "profileName": "BRAF mut STAG2 dec exp STAG3 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}